Prognostic importance of plasma NT‐pro BNP in chronic heart failure in patients treated with a β‐blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial

[1]  A. Rigby,et al.  The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation. , 2006, European heart journal.

[2]  J. Cohn,et al.  Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. , 2006, Clinical chemistry.

[3]  C. Frampton,et al.  NTproBNP‐guided drug treatment for chronic heart failure: design and methods in the “BATTLESCARRED” trial , 2006, European journal of heart failure.

[4]  C. Frampton,et al.  Introduction of Metoprolol Increases Plasma B-Type Cardiac Natriuretic Peptides in Mild, Stable Heart Failure , 2006, Circulation.

[5]  R. Doughty,et al.  Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. , 2006, Journal of the American College of Cardiology.

[6]  J. Cohn,et al.  Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. , 2006, The American journal of medicine.

[7]  T. McDonagh,et al.  N-terminal brain natriuretic peptide, but not anemia, is a powerful predictor of mortality in advanced heart failure. , 2005, Journal of cardiac failure.

[8]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[9]  A. Dobson,et al.  How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review , 2005, BMJ : British Medical Journal.

[10]  T. McDonagh,et al.  N‐terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin‐1, adrenomedullin and tumour necrosis factor‐α in patients referred for consideration of cardiac transplantation , 2005, European journal of heart failure.

[11]  A. Ferreira,et al.  N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients , 2004, Circulation.

[12]  A. Hoffmeier,et al.  Aminoterminal pro type B natriuretic peptide as a predictive and prognostic marker in patients with chronic heart failure. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[13]  J. Rouleau,et al.  Prognostic Impact of Plasma N-Terminal Pro–Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure: A Substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial , 2004, Circulation.

[14]  Hugo A Katus,et al.  NT‐proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT‐proBNP substudy , 2004, European journal of heart failure.

[15]  James D. Thomas,et al.  Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. , 2004, Journal of the American College of Cardiology.

[16]  P. Fischer,et al.  Concentrations of N-terminal pro-brain natriuretic peptide and troponin T in plasma of 75-year-old apparently healthy persons , 2004, Clinical chemistry and laboratory medicine.

[17]  A. Ferreira,et al.  Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. , 2004, International journal of cardiology.

[18]  J. Sanderson,et al.  Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. , 2003, The American journal of cardiology.

[19]  I. Squire,et al.  Pre‐discharge, but not admission, levels of NT‐proBNP predict adverse prognosis following acute LVF , 2003, European journal of heart failure.

[20]  J. Rouleau,et al.  Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine. , 2003, American heart journal.

[21]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[22]  L. Fisher,et al.  Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) , 2003, Circulation.

[23]  P. Macfarlane,et al.  Can natriuretic peptides be used to monitor the response to carvedilol in patients with ischaemic left ventricular systolic dysfunction , 2002 .

[24]  P. Poole‐Wilson,et al.  Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET , 2002, European journal of heart failure.

[25]  R. Berger,et al.  Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. , 2002, European heart journal.

[26]  M. Farrer,et al.  Left ventricular remodelling and brain natriuretic peptide after first myocardial infarction , 2001, Heart.

[27]  E. Hartter,et al.  Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.

[28]  R. Doughty,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. , 2001, Journal of the American College of Cardiology.

[29]  L. Lenert,et al.  A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. , 2001, Journal of the American College of Cardiology.

[30]  M. Kinoshita,et al.  High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. , 2000, Journal of the American College of Cardiology.

[31]  K. Swedberg.  Importance of neuroendocrine activation in chronic heart failure. Impact on treatment strategies , 2000, European journal of heart failure.

[32]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[33]  B. Williams,et al.  Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N terminal proBNP , 2000, Heart.

[34]  R. McKelvie,et al.  Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study. , 2000, Circulation.

[35]  R. Doughty,et al.  Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. , 1999, Circulation.

[36]  J. Karl,et al.  Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. , 1999, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[37]  A. Richards,et al.  The Role of the Circulation in Processing pro-Brain Natriuretic Peptide (proBNP) to Amino-Terminal BNP and BNP-32 , 1997, Peptides.

[38]  A. Richards,et al.  The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. , 1995, Biochemical and biophysical research communications.

[39]  D. Schocken,et al.  Three Peptides From the Atrial Natriuretic Factor Prohormone Amino Terminus Lower Blood Pressure and Produce Diuresis, Natriuresis, and/or Kaliuresis in Humans , 1994, Circulation.

[40]  M. A. Plant.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality , 1991 .

[41]  K. Swedberg,et al.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.

[42]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.